title: TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome.
abstract: Antiphospholipid syndrome (APS) is characterized by thromboses and/or pregnancy losses. Laboratory criterion for the diagnosis of APS is the presence of antiphospholipid antibodies (anticardiolipin, anti-beta2-glycoprotein I (aβ2gpI) and lupus anticoagulant). On the one hand, the latest classification criteria for the diagnosis of APS emphasized that thrombotic manifestations of the syndrome should be without any signs of an inflammatory process, while on the other hand, some recent reports have suggested that APS is a "pro-inflammatory state." This article is focused on the importance of TNF-alpha and annexin A2 (anxA2) for patients with vascular (thrombotic) manifestations of the primary APS. The classic antithrombotic and antiplatelet therapy does not protect APS patients from the development of recurrent thrombosis. Therefore, an urgent need for the introduction of new therapeutic approaches in the treatment of APS patients is obvious. This review provides a rationale for the necessity for the use of immunomodulatory medications that could interfere with β2gpI binding to its receptor(s), such as anxA2, and/or inhibit TNF-alpha activity.
authors.affiliation: Department of Pharmacy, Medical Faculty, University of Novi Sad, Hajduk Veljkova 3, Novi Sad, 21000, Serbia. bmmb4832@gmail.com.
authors.forename: Mirjana
authors.initials: M
authors.lastname: Bećarević
mesh_terms: D017306:Annexin A2 / Q000378:metabolism*; D016736:Antiphospholipid Syndrome / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D013927:Thrombosis / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D017306:Annexin A2; D014409:Tumor Necrosis Factor-alpha
keywords: Annexin A2; Antiphospholipid antibodies; Primary antiphospholipid syndrome; Tumor necrosis factor alpha